Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""kinase"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 510794
Tytuł:
The TAM Subfamily of Receptor Tyrosine Kinases: The Early Years.
Autorzy:
Prieto AL; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405, USA.
Lai C; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405, USA.; Gill Center for Biomolecular Science, Indiana University, Bloomington, IN 47405, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Mar 16; Vol. 25 (6). Date of Electronic Publication: 2024 Mar 16.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Axl Receptor Tyrosine Kinase*
Proto-Oncogene Proteins*/genetics
c-Mer Tyrosine Kinase/genetics ; Receptor Protein-Tyrosine Kinases/genetics ; Receptor Protein-Tyrosine Kinases/chemistry ; Tamoxifen ; Tyrosine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas.
Autorzy:
Cruz SM; Division of Surgical Oncology, Department of Surgery, University of California Davis, Sacramento, CA 95817, USA.
Iranpur KR; Division of Surgical Oncology, Department of Surgery, University of California Davis, Sacramento, CA 95817, USA.
Judge SJ; Division of Surgical Oncology, Department of Surgery, University of California Davis, Sacramento, CA 95817, USA.
Ames E; Department of Pathology, Stanford University, Stanford, CA 94305, USA.
Sturgill IR; Bioinformatics and Computational Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Farley LE; Division of Surgical Oncology, Department of Surgery, University of California Davis, Sacramento, CA 95817, USA.
Darrow MA; Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA 95817, USA.
Crowley JS; Division of Surgical Oncology, Department of Surgery, University of California Davis, Sacramento, CA 95817, USA.
Monjazeb AM; Department of Radiation Oncology, University of California Davis, Sacramento, CA 95817, USA.
Murphy WJ; Department of Dermatology, University of California Davis, Sacramento, CA 95817, USA.
Canter RJ; Division of Surgical Oncology, Department of Surgery, University of California Davis, Sacramento, CA 95817, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Mar 15; Vol. 25 (6). Date of Electronic Publication: 2024 Mar 15.
Typ publikacji:
Journal Article
MeSH Terms:
Tyrosine Kinase Inhibitors*
Sarcoma*/pathology
Humans ; Sorafenib/pharmacology ; Sorafenib/therapeutic use ; Sorafenib/metabolism ; Aldehyde Dehydrogenase/metabolism ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/metabolism ; Neoplastic Stem Cells/metabolism ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
DUSP22 Ameliorates Endothelial-to-Mesenchymal Transition in HUVECs through Smad2/3 and MAPK Signaling Pathways.
Autorzy:
Chen L; Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Su H; Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Tao Z; Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Liang C; Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Liu Z; Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Dong Y; Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zheng P; Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Liu Y; Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Pokaż więcej
Źródło:
Cardiovascular therapeutics [Cardiovasc Ther] 2024 Mar 08; Vol. 2024, pp. 5583961. Date of Electronic Publication: 2024 Mar 08 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
MAP Kinase Signaling System*
Phosphoprotein Phosphatases*
Humans ; Down-Regulation ; Dual-Specificity Phosphatases/genetics ; Endothelial-Mesenchymal Transition ; Human Umbilical Vein Endothelial Cells ; Mitogen-Activated Protein Kinase Phosphatases/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Investigation of Gastrointestinal Toxicities Associated with Concurrent Abdominal Radiation Therapy and the Tyrosine Kinase Inhibitor Sunitinib in a Mouse Model.
Autorzy:
Prebble AR; Veterinary Teaching Hospital, Colorado State University, Fort Collins, CO 80523, USA.
Latka B; Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
Burdekin B; Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
Leary D; Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO 80523, USA.
Harris M; Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA.
Regan D; Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA.
Boss MK; Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 02; Vol. 25 (3). Date of Electronic Publication: 2024 Feb 02.
Typ publikacji:
Journal Article
MeSH Terms:
Tyrosine Kinase Inhibitors*
Indoles*/therapeutic use
Humans ; Animals ; Dogs ; Mice ; Sunitinib/adverse effects ; Ki-67 Antigen ; Pyrroles/adverse effects ; Protein Kinase Inhibitors/adverse effects ; Disease Models, Animal ; Weight Loss
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Intrinsic resistance to ROS1 inhibition in a patient with CD74-ROS1 mediated by AXL overexpression.
Autorzy:
Peters TL; Enliven Therapeutics, Inc., Boulder, Colorado, USA.
Chen N; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Tyler LC; OnKure Therapeutics, Inc., Boulder, Colorado, USA.
Le AT; Cell Technologies Shared Resources, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Dimou A; Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Doebele RC; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2023 Nov; Vol. 14 (33), pp. 3259-3265. Date of Electronic Publication: 2023 Sep 19.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/metabolism
Axl Receptor Tyrosine Kinase*/genetics
Axl Receptor Tyrosine Kinase*/metabolism
Humans ; Drug Resistance, Neoplasm/genetics ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Protein-Tyrosine Kinases/genetics ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins/metabolism ; Oncogene Proteins, Fusion/metabolism ; Tyrosine Kinase Inhibitors/pharmacology ; Tyrosine Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Binding selectivity analysis of AURKs inhibitors through molecular dynamics simulation studies.
Autorzy:
Alharthy RD; Department of Chemistry, Science and Arts College, King Abdulaziz University, Jeddah, Saudi Arabia.
Fatima G; Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan.
Yousaf N; Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan.
Iqbal MS; Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan.
Sattar S; Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan.
Alanzi AR; Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Ali I; Centre for Applied Mathematics and Bioinformatics (CAMB), Gulf University for Science and Technology, Hawally, Kuwait.
Muddassar M; Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Dec 19; Vol. 18 (12), pp. e0295741. Date of Electronic Publication: 2023 Dec 19 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Aurora Kinase A*/metabolism
Molecular Dynamics Simulation*
Aurora Kinase B/metabolism ; Protein Kinase Inhibitors/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Recent Progress in CDK4/6 Inhibitors and PROTACs.
Autorzy:
Wang H; Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University Jinming Campus, Kaifeng 475004, China.
Ba J; Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University Jinming Campus, Kaifeng 475004, China.
Kang Y; Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University Jinming Campus, Kaifeng 475004, China.
Gong Z; Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University Jinming Campus, Kaifeng 475004, China.
Liang T; Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University Jinming Campus, Kaifeng 475004, China.
Zhang Y; Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University Jinming Campus, Kaifeng 475004, China.
Qi J; Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University Jinming Campus, Kaifeng 475004, China.
Wang J; Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University Jinming Campus, Kaifeng 475004, China.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2023 Dec 13; Vol. 28 (24). Date of Electronic Publication: 2023 Dec 13.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Cyclin-Dependent Kinase 6*
Breast Neoplasms*/drug therapy
Humans ; Female ; Cyclin-Dependent Kinase 4 ; Proteolysis ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers.
Autorzy:
Shan KS; Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA.
Rehman TU; Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA.
Ivanov S; Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA.
Domingo G; Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA.
Raez LE; Memorial Health Care, Thoracic Oncology Program, Pembroke Pines, FL 33328, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 03; Vol. 25 (1). Date of Electronic Publication: 2024 Jan 03.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Melanoma*/drug therapy
Melanoma*/genetics
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Humans ; Mitogen-Activated Protein Kinase Kinases ; Mitogen-Activated Protein Kinases ; Molecular Targeted Therapy ; Proto-Oncogene Proteins B-raf/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.
Autorzy:
Wang P; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450000, China.; Tianjian Laboratory for Advanced Biomedical Sciences, Zhengzhou, 450052, Henan, China.; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Laster K; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Jia X; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450000, China.; Tianjian Laboratory for Advanced Biomedical Sciences, Zhengzhou, 450052, Henan, China.; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Dong Z; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450000, China. .; Tianjian Laboratory for Advanced Biomedical Sciences, Zhengzhou, 450052, Henan, China. .; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China. .; Department of Pathophysiology, School of Basic Medical Sciences, China-US (Henan) Hormel Cancer Institute, AMS, College of Medicine, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, 450001, Henan, China. .
Liu K; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450000, China. .; Tianjian Laboratory for Advanced Biomedical Sciences, Zhengzhou, 450052, Henan, China. .; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China. .; Department of Pathophysiology, School of Basic Medical Sciences, China-US (Henan) Hormel Cancer Institute, AMS, College of Medicine, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, 450001, Henan, China. .; Basic Medicine Sciences Research Center, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450052, Henan, China. .; State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou, 450000, Henan, China. .; Provincial Cooperative Innovation Center for Cancer Chemoprevention, Zhengzhou University, Zhengzhou, 450000, Henan, China. .
Pokaż więcej
Źródło:
Molecular cancer [Mol Cancer] 2023 Dec 18; Vol. 22 (1), pp. 208. Date of Electronic Publication: 2023 Dec 18.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Proto-Oncogene Proteins B-raf*
MAP Kinase Signaling System*
Humans ; Cell Line, Tumor ; Signal Transduction ; Phosphorylation ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins c-raf/genetics ; Proto-Oncogene Proteins c-raf/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Synergistic lethality in chronic myeloid leukemia - targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment.
Autorzy:
Häselbarth L; Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany. .; Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg (CCC-ER-EMN), Erlangen, Germany. .; Interdisciplinary Centre for Clinical Research (IZKF), Erlangen, Germany. .
Gamali S; Department of Internal Medicine 5, Hematology and Oncology, University Hospital Erlangen, Erlangen, Germany.
Saul D; Department of Internal Medicine 5, Hematology and Oncology, University Hospital Erlangen, Erlangen, Germany.
Krumbholz M; Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg (CCC-ER-EMN), Erlangen, Germany.
Böttcher-Loschinski R; Department of Hematology and Oncology, Medical Center, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.
Böttcher M; Department of Hematology and Oncology, Medical Center, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.; Health Campus Immunology, Inflammation and Infectiology (GC-I3), Medical Center, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.
Zou D; Department of Hematology and Oncology, Medical Center, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.
Metzler M; Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg (CCC-ER-EMN), Erlangen, Germany.; Interdisciplinary Centre for Clinical Research (IZKF), Erlangen, Germany.
Karow A; Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg (CCC-ER-EMN), Erlangen, Germany.; Interdisciplinary Centre for Clinical Research (IZKF), Erlangen, Germany.
Mougiakakos D; Department of Hematology and Oncology, Medical Center, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.; Health Campus Immunology, Inflammation and Infectiology (GC-I3), Medical Center, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Nov 27; Vol. 23 (1), pp. 1153. Date of Electronic Publication: 2023 Nov 27.
Typ publikacji:
Journal Article
MeSH Terms:
Tyrosine Kinase Inhibitors*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/metabolism
Humans ; Fusion Proteins, bcr-abl ; Oxidative Phosphorylation ; Thapsigargin/pharmacology ; Thapsigargin/therapeutic use ; Drug Resistance, Neoplasm ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Enzyme Inhibitors/pharmacology ; Oligomycins/pharmacology ; Adenosine Triphosphate/metabolism ; Apoptosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Seize the engine: Emerging cell cycle targets in breast cancer.
Autorzy:
Fuentes-Antrás J; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.; NEXT Oncology, Hospital Universitario QuironSalud Madrid, Madrid, Spain.
Bedard PL; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Cescon DW; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2024 Jan; Vol. 14 (1), pp. e1544.
Typ publikacji:
Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Aurora Kinase A*
Neoplasms*
Cell Cycle ; Cell Division ; Cell Proliferation ; Cyclin-Dependent Kinase Inhibitor Proteins
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
CD147 promotes breast cancer migration and invasion by inducing epithelial-mesenchymal transition via the MAPK/ERK signaling pathway.
Autorzy:
Li F; Department of Scientific Research, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, 030032, PR China. lifang_.
Wang J; Department of Neurosurgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, 030032, PR China.
Yan YQ; Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Institute of Biotechnology, Shanxi University, Taiyuan, 030006, PR China.
Bai CZ; Central Laboratory, Shanxi Province Hospital of Traditional Chinese Medicine, Taiyuan, 030012, PR China.
Guo JQ; Department of Clinical Laboratory, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, 030032, PR China.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Dec 08; Vol. 23 (1), pp. 1214. Date of Electronic Publication: 2023 Dec 08.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/genetics
Breast Neoplasms*/pathology
MAP Kinase Signaling System*
Basigin*/genetics
Female ; Humans ; Cadherins/metabolism ; Cell Line, Tumor ; Cell Movement ; Epithelial-Mesenchymal Transition/genetics ; Fluorouracil ; Matrix Metalloproteinase 9/metabolism ; MCF-7 Cells ; Mitogen-Activated Protein Kinase Kinases/metabolism ; Signal Transduction ; Vimentin/genetics ; Vimentin/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
PHI-1, an Endogenous Inhibitor Protein for Protein Phosphatase-1 and a Pan-Cancer Marker, Regulates Raf-1 Proteostasis.
Autorzy:
Kirkbride JA; Department of Molecular Physiology and Biophysics, and Kimmel Cancer Center, Jefferson Medical College, Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA 19107, USA.
Nilsson GY; Department of Molecular Physiology and Biophysics, and Kimmel Cancer Center, Jefferson Medical College, Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA 19107, USA.
Kim JI; Department of Molecular Physiology and Biophysics, and Kimmel Cancer Center, Jefferson Medical College, Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA 19107, USA.; Department of Molecular Medicine, Keimyung University School of Medicine, Daegu 42601, Republic of Korea.
Takeya K; Department of Veterinary Medicine, Faculty of Veterinary Medicine, Okayama University of Science, Imabari 794-8555, Ehime, Japan.
Tanaka Y; Department of Veterinary Medicine, Faculty of Veterinary Medicine, Okayama University of Science, Imabari 794-8555, Ehime, Japan.
Tokumitsu H; Applied Cell Biology, Graduate School of Interdisciplinary Science & Engineering in Health Systems, Okayama University, Okayama 700-8530, Okayama, Japan.
Suizu F; Oncology Pathology, Department of Pathology and Host-Defense, Faculty of Medicine, Kagawa University, Kita-gun 761-0793, Kagawa, Japan.
Eto M; Department of Molecular Physiology and Biophysics, and Kimmel Cancer Center, Jefferson Medical College, Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA 19107, USA.; Department of Veterinary Medicine, Faculty of Veterinary Medicine, Okayama University of Science, Imabari 794-8555, Ehime, Japan.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2023 Dec 04; Vol. 13 (12). Date of Electronic Publication: 2023 Dec 04.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
MAP Kinase Signaling System*/physiology
Neoplasms*
Humans ; Protein Phosphatase 1 ; Proteostasis ; HEK293 Cells ; Mitogen-Activated Protein Kinase Kinases
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
New spiro-indeno[1,2- b ]quinoxalines clubbed with benzimidazole scaffold as CDK2 inhibitors for halting non-small cell lung cancer; stereoselective synthesis, molecular dynamics and structural insights.
Autorzy:
Barakat A; Department of Chemistry, College of Science, King Saud University, Riyadh, Saudi Arabia.
Alshahrani S; Department of Chemistry, College of Science, King Saud University, Riyadh, Saudi Arabia.
Al-Majid AM; Department of Chemistry, College of Science, King Saud University, Riyadh, Saudi Arabia.
Alamary AS; Department of Chemistry, College of Science, King Saud University, Riyadh, Saudi Arabia.
Haukka M; Department of Chemistry, University of Jyväskylä, Jyväskylä, Finland.
Abu-Serie MM; Medical Biotechnology Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Egypt.
Domingo LR; Department of Organic Chemistry, University of Valencia, Burjassot, Valencia, Spain.
Ashraf S; Dr. Panjwani Center for Molecular medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Ul-Haq Z; Dr. Panjwani Center for Molecular medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Nafie MS; Department of Chemistry, College of Sciences, University of Sharjah, Sharjah, UAE.; Chemistry Department, Faculty of Science, Suez Canal University, Ismailia, Egypt.
Teleb M; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2281260. Date of Electronic Publication: 2023 Nov 23.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/chemistry
Carcinoma, Non-Small-Cell Lung*/drug therapy
Cyclin-Dependent Kinase 2*/antagonists & inhibitors
Lung Neoplasms*/drug therapy
Humans ; Benzimidazoles/pharmacology ; Cell Proliferation ; Drug Screening Assays, Antitumor ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Molecular Structure ; Protein Kinase Inhibitors/chemistry ; Quinoxalines
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Rat and mouse cardiomyocytes show subtle differences in creatine kinase expression and compartmentalization.
Autorzy:
Branovets J; Laboratory of Systems Biology, Department of Cybernetics, Tallinn University of Technology, Tallinn, Estonia.
Soodla K; Laboratory of Systems Biology, Department of Cybernetics, Tallinn University of Technology, Tallinn, Estonia.
Vendelin M; Laboratory of Systems Biology, Department of Cybernetics, Tallinn University of Technology, Tallinn, Estonia.
Birkedal R; Laboratory of Systems Biology, Department of Cybernetics, Tallinn University of Technology, Tallinn, Estonia.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Nov 27; Vol. 18 (11), pp. e0294718. Date of Electronic Publication: 2023 Nov 27 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Myocytes, Cardiac*/metabolism
Creatine Kinase*/metabolism
Rats ; Mice ; Animals ; Mitochondria/metabolism ; Adenylate Kinase/metabolism ; Protein Isoforms/metabolism ; Adenosine Diphosphate/metabolism ; Creatine/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.
Autorzy:
Chen W; Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Park JI; Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Oct 02; Vol. 24 (19). Date of Electronic Publication: 2023 Oct 02.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Proto-Oncogene Proteins B-raf*/metabolism
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
MAP Kinase Kinase 1/genetics ; Cell Line, Tumor ; Signal Transduction ; Drug Resistance, Neoplasm/genetics ; Mutation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A Workflow Combining Machine Learning with Molecular Simulations Uncovers Potential Dual-Target Inhibitors against BTK and JAK3.
Autorzy:
Liu L; Institute of Theoretical Chemistry, Jilin University, Changchun 130061, China.
Na R; Collaborative Innovation Center of Henan Grain Crops, National Key Laboratory of Wheat and Maize Crop Science, College of Plant Protection, Henan Agricultural University, Zhengzhou 450002, China.
Yang L; Department of Medical Mycology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.
Liu J; Institute of Theoretical Chemistry, Jilin University, Changchun 130061, China.
Tan Y; Institute of Theoretical Chemistry, Jilin University, Changchun 130061, China.
Zhao X; Institute of Theoretical Chemistry, Jilin University, Changchun 130061, China.
Huang X; Institute of Theoretical Chemistry, Jilin University, Changchun 130061, China.
Chen X; Department of Nanomaterials Physicochemistry, Faculty of Chemical Technology and Engineering, West Pomeranian University of Technology, Szczecin Piastów Ave. 42, 71-065 Szczecin, Poland.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2023 Oct 17; Vol. 28 (20). Date of Electronic Publication: 2023 Oct 17.
Typ publikacji:
Journal Article
MeSH Terms:
Janus Kinase 3*
Lymphoma, B-Cell*
Humans ; Agammaglobulinaemia Tyrosine Kinase ; Workflow ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data.
Autorzy:
Villa F; Medical Oncology, Oncology Department ASST Lecco, 23900 Lecco, Italy.
Crippa A; Medical Oncology, Oncology Department ASST Lecco, 23900 Lecco, Italy.
Pelizzoni D; Medical Oncology, Oncology Department ASST Lecco, 23900 Lecco, Italy.
Ardizzoia A; School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milano, Italy.
Scartabellati G; Medical Oncology, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.; Department of Medical and Surgical Specialties, Medical Oncology, University of Brescia, 25121 Brescia, Italy.
Corbetta C; Medical Oncology, Oncology Department ASST Lecco, 23900 Lecco, Italy.
Cipriani E; Medical Oncology, Oncology Department ASST Lecco, 23900 Lecco, Italy.
Lavitrano M; School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milano, Italy.
Ardizzoia A; Medical Oncology, Oncology Department ASST Lecco, 23900 Lecco, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Sep 22; Vol. 24 (19). Date of Electronic Publication: 2023 Sep 22.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Cyclin-Dependent Kinase 6*
Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Humans ; Female ; Cyclin-Dependent Kinase 4 ; Cell Cycle ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A Multimodel Study of the Role of Novel PKC Isoforms in the DNA Integrity Checkpoint.
Autorzy:
Saiz-Baggetto S; Departament de Bioquímica i Biologia Molecular, Universitat de València, 46100 Burjassot, Spain.; Institut de Biotecnologia i Biomedicina (BIOTECMED), Universitat de València, 46100 Burjassot, Spain.
Dolz-Edo L; Departament de Bioquímica i Biologia Molecular, Universitat de València, 46100 Burjassot, Spain.; Institut de Biotecnologia i Biomedicina (BIOTECMED), Universitat de València, 46100 Burjassot, Spain.; Departament de Biologia Cellular, Biologia Funcional i Antropologia Física, Universitat de València, 46100 Burjassot, Spain.
Méndez E; Departament de Bioquímica i Biologia Molecular, Universitat de València, 46100 Burjassot, Spain.; Institut de Biotecnologia i Biomedicina (BIOTECMED), Universitat de València, 46100 Burjassot, Spain.
García-Bolufer P; Institut de Biotecnologia i Biomedicina (BIOTECMED), Universitat de València, 46100 Burjassot, Spain.; Departament de Biologia Cellular, Biologia Funcional i Antropologia Física, Universitat de València, 46100 Burjassot, Spain.
Marí M; Institut de Biotecnologia i Biomedicina (BIOTECMED), Universitat de València, 46100 Burjassot, Spain.; Departament de Biologia Cellular, Biologia Funcional i Antropologia Física, Universitat de València, 46100 Burjassot, Spain.
Bañó MC; Departament de Bioquímica i Biologia Molecular, Universitat de València, 46100 Burjassot, Spain.; Institut de Biotecnologia i Biomedicina (BIOTECMED), Universitat de València, 46100 Burjassot, Spain.
Fariñas I; Institut de Biotecnologia i Biomedicina (BIOTECMED), Universitat de València, 46100 Burjassot, Spain.; Departament de Biologia Cellular, Biologia Funcional i Antropologia Física, Universitat de València, 46100 Burjassot, Spain.
Morante-Redolat JM; Institut de Biotecnologia i Biomedicina (BIOTECMED), Universitat de València, 46100 Burjassot, Spain.; Departament de Biologia Cellular, Biologia Funcional i Antropologia Física, Universitat de València, 46100 Burjassot, Spain.
Igual JC; Departament de Bioquímica i Biologia Molecular, Universitat de València, 46100 Burjassot, Spain.; Institut de Biotecnologia i Biomedicina (BIOTECMED), Universitat de València, 46100 Burjassot, Spain.
Quilis I; Departament de Bioquímica i Biologia Molecular, Universitat de València, 46100 Burjassot, Spain.; Institut de Biotecnologia i Biomedicina (BIOTECMED), Universitat de València, 46100 Burjassot, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Oct 31; Vol. 24 (21). Date of Electronic Publication: 2023 Oct 31.
Typ publikacji:
Journal Article
MeSH Terms:
Protein Kinase C*/genetics
Protein Kinase C*/metabolism
Saccharomyces cerevisiae*/genetics
Saccharomyces cerevisiae*/metabolism
Animals ; Mice ; Isoenzymes/genetics ; Isoenzymes/metabolism ; Mammals/metabolism ; DNA ; Protein Kinase C-delta/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Aurora kinase B relocation blocker LXY18 triggers mitotic catastrophe selectively in malignant cells.
Autorzy:
Kalashova J; Division of Discovery Oncology, Chengdu Anticancer Bioscience, Chengdu, Sichuan, China.; Department of Basic Cancer Research, J. Michael Bishop Institute of Cancer Research, Chengdu, Sichuan, China.
Yang C; Division of Discovery Oncology, Chengdu Anticancer Bioscience, Chengdu, Sichuan, China.; Department of Basic Cancer Research, J. Michael Bishop Institute of Cancer Research, Chengdu, Sichuan, China.
Li H; Division of Discovery Oncology, Chengdu Anticancer Bioscience, Chengdu, Sichuan, China.; Department of Basic Cancer Research, J. Michael Bishop Institute of Cancer Research, Chengdu, Sichuan, China.
Long Y; Division of Discovery Oncology, Chengdu Anticancer Bioscience, Chengdu, Sichuan, China.; Department of Basic Cancer Research, J. Michael Bishop Institute of Cancer Research, Chengdu, Sichuan, China.
Yu D; Division of Discovery Oncology, Chengdu Anticancer Bioscience, Chengdu, Sichuan, China.
Zhang T; Division of Discovery Oncology, Chengdu Anticancer Bioscience, Chengdu, Sichuan, China.; Department of Basic Cancer Research, J. Michael Bishop Institute of Cancer Research, Chengdu, Sichuan, China.
Liu X; Division of Discovery Oncology, Chengdu Anticancer Bioscience, Chengdu, Sichuan, China.
Choudhry N; Division of Discovery Oncology, Chengdu Anticancer Bioscience, Chengdu, Sichuan, China.; Department of Basic Cancer Research, J. Michael Bishop Institute of Cancer Research, Chengdu, Sichuan, China.
Shi Q; Division of Discovery Oncology, Chengdu Anticancer Bioscience, Chengdu, Sichuan, China.; Department of Basic Cancer Research, J. Michael Bishop Institute of Cancer Research, Chengdu, Sichuan, China.
Allen TD; Division of Discovery Oncology, Chengdu Anticancer Bioscience, Chengdu, Sichuan, China.; Department of Basic Cancer Research, J. Michael Bishop Institute of Cancer Research, Chengdu, Sichuan, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Oct 30; Vol. 18 (10), pp. e0293283. Date of Electronic Publication: 2023 Oct 30 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Aurora Kinase A*
Neoplasms*/drug therapy
Humans ; Aurora Kinase B/genetics ; Aurora Kinase B/metabolism ; Cell Death ; Mitosis ; NIMA-Related Kinases
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 510794

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies